Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Berlin: European stocks rebounded yesterday after four days of declines as Ukraine accepted a ceasefire proposal brokered by the US, while data ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an inhibitor of the ...

Zealand Pharma jumped over 37%, logging its best day on record, after Swiss pharmaceutical company Roche acquired rights to ...

EUROPEAN shares bounced back on Wednesday following four sessions of declines on optimism around positive developments in the ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

Health-care companies fell as traders rotated back into higher risk areas. Swiss drug giant Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.